Hong Kong’s IPO boom extends beyond tech, HKEX CEO says, as fundraising tops $40 billion

HKEX says Hong Kong’s IPO pipeline has more than 100 listings this year, generating over $40B in proceeds—already ahead of the $37B raised in all of 2025—and IPO diversity extends beyond AI/tech into biotech, mining, and consumer. The exchange reported record half-year profits with net profit up 24% to HK$10.57B ($1.35B), beating analysts, while average daily turnover has risen to HK$280B (vs HK$250B for 2025). Follow-on offerings are also strong at over $50B YTD, and the liquidity backdrop is supported by broader global investor participation rather than a single source.

Analysis

The key signal is breadth, not just headline issuance. When a venue can clear healthcare, mining, and consumer deals alongside tech, it suggests the marginal buyer is willing to price cash flows rather than only story stocks, which usually extends the IPO cycle by quarters, not weeks. For HKEX, that matters because primary fees, secondary turnover, and derivatives activity reinforce each other; the market can keep compounding even if one issuance bucket cools.

The second-order winners are the infrastructure names that monetize every extra dollar of flow: brokers, custodians, market-makers, and index/benchmark products tied to Hong Kong volumes. Relative losers are regional competitors that depend on a narrower issuer base; Singapore’s exchange is the cleanest public-market comparison if Hong Kong keeps absorbing Asia listing intent. A more subtle point is that broad issuer diversity lowers single-sector fatigue, so the market is less vulnerable to a sudden tech sentiment reset.

The contrarian risk is that the market is paying for a permanently higher liquidity regime before the hard evidence is durable. IPO markets often look strongest when supply is abundant; if post-listing performance degrades, cornerstone demand can vanish quickly and the pipeline can freeze for 1-2 quarters. The falsifier is simple: if ADT slips back toward prior ranges or follow-on/IPO book quality weakens into year-end, the current optimism should be treated as cyclical rather than structural.

Key Decisions for Investors

• Long HKEX (0388.HK) on pullbacks; thesis is 1-3 month operating leverage from sustained turnover and issuance, with downside limited if volumes merely normalize rather than collapse.
• Pair trade: long HKEX (0388.HK) / short SGX (S68.SI) for 1-3 months; HKEX has the cleaner upside to Asia listing momentum, while SGX is the more likely relative laggard if global issuers keep preferring Hong Kong.
• Watchlist rather than immediate trade: buy Hong Kong broker/execution proxies such as FUTU only if Southbound and ex-mainland participation both keep rising; otherwise the stock can underperform if the mix stays institutional and fees skew to the exchange.
• Set a catalyst alert for HKEX turnover and post-IPO performance over the next 4-8 weeks; if ADT rolls over or new listings trade below issue price, reduce any long HKEX exposure because the fee cycle can reverse faster than consensus expects.